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ABSTRACT
Chronic kidney disease (CKD) is a complex
disease which affects approximately 13% of the
world’s population. Over time, CKD can cause
renal dysfunction and progression to end-stage
kidney disease and cardiovascular disease.
Complications associated with CKD may con-
tribute to the acceleration of disease progression
and the risk of cardiovascular-related morbidi-
ties. Early CKD is asymptomatic, and symptoms
only present at later stages when complications
of the disease arise, such as a decline in kidney
function and the presence of other comorbidi-
ties associated with the disease. In advanced
stages of the disease, when kidney function is
significantly impaired, patients can only be
treated with dialysis or a transplant. With lim-
ited treatment options available, an increasing
prevalence of both the elderly population and
comorbidities associated with the disease, the
prevalence of CKD is set to rise. This review
discusses the current challenges and the unmet
patient need in CKD.
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Key Summary Points
Chronic kidney disease (CKD) affects a
significant proportion of the population
and is growing rapidly owing to an
increased aging population and
prevalence of type 2 diabetes mellitus,
obesity, hypertension and cardiovascular
disease that contribute towards CKD.
CKD progression is strongly associated
with poor clinical outcomes and has a
significant economic burden.
Despite its high prevalence and the
clinical and economic burden of its
associated complications, CKD awareness
remains profoundly low, in part because
CKD is usually silent until its late stages.
Physician awareness of CKD is critical for
the early implementation of evidence-
based therapies that can slow progression
of renal dysfunction, prevent metabolic
complications, and reduce cardiovascular-
related outcomes.
INTRODUCTION
Chronic kidney disease (CKD) is a complex and
multifaceted disease, causing renal dysfunction
and progression to end-stage kidney disease
(ESKD) and cardiovascular disease. Complica-
tions associated with the disease contribute to
the acceleration of CKD progression and risk of
cardiovascular-related morbidities.
Despite its high prevalence and the clinical
and economic burden of its associated compli-
cations, disease awareness remains profoundly
low. Worldwide, only 6% of the general popu-
lation and 10% of the high-risk population are
aware of their CKD statuses [1]. In addition,
CKD recognition in primary care settings is also
suboptimal, ranging from 6% to 50%, depen-
dent upon primary care specialty, severity of
disease, and experience. Awareness of CKD
remains low in part because CKD is usually
silent until its late stages. However, diagnosis of
CKD during the later stages results in fewer
opportunities to prevent adverse outcomes.
Physician awareness of CKD is critical for the
early implementation of evidence-based thera-
pies that can slow progression of renal dys-
function, prevent metabolic complications, and
reduce cardiovascular-related outcomes.
Currently CKD is not curable, and manage-
ment of the disease relies on treatments which
prevent CKD progression and cardiovascular
disease. Despite available treatments, a residual
risk of adverse events and CKD progression
remains. This article reviews the challenges
associated with CKD and the treatments avail-
able for patients, highlighting the unmet need
for cardio-renal protection in patients with
CKD.
This article is based on previously conducted
studies and does not contain any new studies
with human participants or animals performed
by any of the authors.
CKD PREVALENCE
CKD is a global health problem. A meta-analysis
of observational studies estimating CKD preva-
lence showed that approximately 13.4% of the
world’s population has CKD [2]. The majority,
79%, were at late stages of the disease
(stage 3–5); however, the actual proportion of
people with early CKD (stage 1 or 2) is likely to
be much higher since early kidney disease is
clinically silent [3].
Prevalence of CKD appears to be growing
rapidly both in the UK and in the Western
world. Based on the 2012 subnational popula-
tion projections for England [4], the number of
people with CKD stage 3–5 is projected to
exceed 4 million by 2036 [5]. This rise in CKD
prevalence is due to an increased aging popu-
lation and prevalence of type 2 diabetes
(T2DM), obesity, hypertension and cardiovas-
cular disease that contribute to CKD [6–8].
Adv Ther
The World Health Organization (WHO)
estimated that the annual, global number of
deaths caused directly by CKD is 5–10 million
[9]. The presence of CKD advances mortality of
comorbidities such as cardiovascular diseases,
T2DM, hypertension, and infection with
human immunodeficiency virus (HIV), malaria
and Covid-19, thereby indirectly adding to CKD
mortality [9, 10]. A contributing cause of high
morbidity and mortality associated with CKD is
a lack of awareness of the disease, by both
patients and providers [11, 12]. Early stages of
CKD are clinically silent and patients have no
symptoms. Lack of treatment at this stage
allows CKD to progress through to advanced
stages of the disease, where patients may pre-
sent complications and/or cardiovascular-re-
lated comorbidities, or ESKD. Raising awareness
of CKD is therefore paramount to allow for early
intervention and reduce the risk of comorbidi-
ties and mortality.
CLASSIFICATION OF CKD
In order to better manage CKD and provide
better care for patients, the classification of CKD
was developed by the National Kidney Foun-
dation Kidney Disease Outcomes Quality Ini-
tiative [13] and the international guideline
group Kidney Disease Improving Global Out-
comes (KDIGO) [14]. CKD stratification is based
upon the estimated glomerular filtration rate
(eGFR) and albuminuria.
There are six eGFR categories. An eGFR of
less than 60 mL/min per 1.73 m2 for more than
3 months is indicative of impaired renal func-
tion and the severity of kidney damage increa-
ses with decreasing eGFR measurements.
Patients with early onset of the disease,
stage 1–2, have normal to mild decreased levels
of eGFR (60 to C 90 mL/min per 1.73 m2).
Patients with stage 3a–3b have mild to moder-
ate decreased levels of eGFR (45–59 mL/min per
1.73 m2, respectively). Severely decreased levels
of eGFR, stage 4–5 (15–29 to \15 mL/min per
1.73 m2, respectively), are indicative of
advanced stages of the disease and kidney
failure.
Stratification also comprises three categories
of albuminuria. Patients with an albumin to
creatinine ratio (ACR) of 3 to at most 30 mg/
mmol are classified as having microalbuminuria
and at moderate risk of adverse outcomes.
Those with ACR of greater than 30 mg/mmol
are classified as having macroalbuminuria and
being severely at risk of developing adverse
events [15]. The eGFR and albuminuria cate-
gories independently predict adverse outcomes
for patients with CKD, and the combination of
both increases this risk further [16]. The CKD
classification system aids clinicians in carrying
out accurate assessments of CKD severity and
other complications which helps to inform
decisions associated with the management and
monitoring of patients [3, 17, 18].
CLINICAL BURDEN OF CKD
CKD is a complex disease, involving both non-
modifiable (e.g. older age, family history and
ethnicity) and modifiable risk factors (e.g.
T2DM, hypertension and dyslipidaemia) which
are responsible for the initiation of early CKD,
CKD progression (stage 3–5) and ESKD.
In early stages of CKD (stage 1–2), factors
such as hypertension, obesity and T2DM can
trigger kidney function impairment. This causes
glomerular/interstitial damage and results in
impaired glomerular filtration, leading to
decreased eGFR and increased albuminuria. At
this stage, even though clinical symptoms do
not present, the presence of additional risk
factors, including hypertension, hypergly-
caemia, smoking, obesity, dyslipidaemia and
cardiovascular disease, may accelerate CKD
progression and result in ESKD.
As the disease progresses, the clinical and
economic burden of CKD increases (Fig. 1) as
complications such as CKD mineral bone dis-
order, anaemia, hypertension and hyper-
kalaemia may occur and advanced stages of
CKD, stage 4–5, ensue. Clinical symptoms, such
as fatigue, itching of the skin, bone or joint
pain, muscle cramps and swollen ankles, feet or
hands, are often present at this stage [19]. Fur-
ther deterioration of kidney function causes
tubular and glomerular hypertrophy, sclerosis
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and fibrosis, leading to a significant reduction
in eGFR, extreme albuminuria and kidney
failure.
Even though CKD progression may lead to
kidney failure and renal death, patients with
CKD are more likely to die from cardiovascular-
related complications before reaching ESKD
[20]. A study using data from a meta-analysis
involving 1.4 million individuals found a sig-
nificant increased risk of cardiovascular-related
mortality, even in stage 2 of CKD (eGFR
levels\ 90 mL/min per 1.73 m2) [16, 21, 22].
As the disease progresses, the risk of cardio-
vascular disease is markedly increased, such that
50% of patients with late-stage CKD, stage 4–5,
have cardiovascular disease. The risk of atrial
fibrillation (AF) and acute coronary syndrome
(ACS) is doubled in patients with
eGFR\ 60 mL/min per 1.73 m2. AF is associated
with a threefold higher risk of progression to
ESKD. The incidence of heart failure (HF) is also
threefold greater in patients with
eGFR\ 60 mL/min per 1.73 m2 compared with
[90 mL/min per 1.73 m2 and HF is associated
with CKD progression, hospitalisation and
death [23].
The increased risk of cardiovascular disease
in patients with CKD is due in part to the tra-
ditional risk factors associated with
cardiovascular disease such as hypertension,
T2DM and dyslipidaemia. For instance, a large
observational database linked study (Third
National Health and Nutrition Examination
Survey (NHANES) III) found a strong association
between CKD and T2DM combined and an
increased risk of mortality [24]. In this study,
the authors observed a 31.1% mortality rate in
patients with CKD and diabetes, compared to
11.5% in people with diabetes only. An obser-
vational study using both US and UK linked
databases showed that the presence of both
CKD and T2DM was related to increased risk of
major adverse cardiac events (MACE), HF and
arrhythmogenic cardiomyopathy (ACM) [25].
This risk was further elevated in older patients
with atherosclerotic cardiovascular disease [25].
Similarly, the presence of both CKD and T2DM
leads to a significant increased risk of all-cause
and cardiovascular-related mortality versus
T2DM alone [24].
The direct renal effect on cardiovascular
disease is due to generalised inflammatory
change, cardiac remodelling, narrowing of the
arteries and vascular calcification, both con-
tributing to the acceleration of vascular ageing
and atherosclerotic processes, and leading to
myocardial infarction, stroke and HF [26].
Fig. 1 A schematic diagram showing the association between CKD progression and clinical and economic burden.
Symptoms of CKD typically present during advanced stages of the disease where patients are at increased risk of
cardiovascular disease and other comorbidities
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Together, these studies highlight the strong
relationship which exists between CKD pro-
gression, number of comorbidities and height-
ened risk of cardiovascular disease and
cardiovascular-related mortality.
ECONOMIC BURDEN OF CKD
In addition to the clinical burden, management
of CKD also requires significant healthcare
resources and utilisation. In 2009–2010, the
estimated cost of CKD to the National Health
Service (NHS) in England was £1.45 billion [27].
Furthermore, in 2016, US Medicare combined
expenditure for CKD and ESKD exceeded
$114 billion (£86 billion) [28].
Although estimating the true cost of early
CKD is difficult because of the lack of data
available for unreported cases, CKD progression
is associated with increased healthcare costs
[29, 30]. A study by Honeycutt et al. combined
laboratory data from NHANES with expenditure
data from Medicare and found that costs of CKD
management increased with disease progression
[29]. Estimated annual medical costs of CKD per
person were not significant at stage 1, $1700 at
stage 2, $3500 at stage 3 and $12,700 at stage 4.
Healthcare costs associated with early CKD
are more likely to be from the sequalae of
comorbid disease rather than kidney disease.
Hence, patients with CKD stage 1 or 2 are at
increased risk of hospitalisation if they also
have T2DM (9%), cardiovascular disease (more
than twofold), and both cardiovascular disease
and T2DM (approximately fourfold) [31].
ESKD accounts for the largest proportion of
CKD management costs. In 2009–2010, 50% of
the overall CKD cost to NHS (England) was due
to renal replacement therapy (RRT), which
accounted for 2% of the CKD population [27].
The other 50% included renal primary care
costs, such as treatment costs for hypertension
and tests, consultation costs, non-renal care
attributable to CKD and renal secondary care
costs. Approximately £174 million was esti-
mated for the annual cost of myocardial
infarctions and strokes associated with CKD
[27].
More recently, an economic analysis inves-
tigated the burden associated with the man-
agement of cardiovascular-related morbidity
and mortality in CKD, according to the KDIGO
categorisation of both eGFR and albuminuria
[15]. Decreased eGFR levels increased both the
risk of adverse clinical outcomes and economic
costs, and albuminuria elevated this risk signif-
icantly. Furthermore, CKD progression corre-
lated with increased CKD management costs
and bed days. Stage 5 CKD (versus stage 1 (or
without) CKD) per 1000 patient years was asso-
ciated with £435,000 in additional costs and
1017 bed days.
The significant economic burden associated
with CKD progression and ESKD highlights the
importance of optimising CKD management
and the unmet need for better treatment
options in slowing disease progression in this
patient population. Thus, early detection and
intervention to slow the progression of the
disease has the potential to make substantial
savings in healthcare costs.
CURRENT CKD MANAGEMENT
STRATEGIES
KDIGO and National Institute for Health and
Care Excellence (NICE) have produced detailed
guidelines for the evaluation and management
of CKD [3, 32, 33]. Both recommend imple-
menting strategies for early diagnosis of the
disease in order to reduce the risk of cardiovas-
cular disease, attenuate CKD progression and
decrease the incidence of ESKD in this patient
population. CKD is a complex disease and thus
treatment requires a multifaceted approach
utilising both non-pharmacological, e.g. diet
and exercise regimes and pharmacological
interventions such as antihypertensive and
antihyperglycemic drugs [34]. There has, how-
ever, been no significant breakthrough in this
area for over 2 decades.
The effect of lifestyle intervention on
reducing disease progression is still unclear,
although increased physical activity has been
shown to slow the rate of eGFR decline [35] and
ESKD progression [36], improve eGFR levels [35]
and albuminuria [37], and reduce mortality in
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patients with CKD [35, 38–40]. Similarly, diet
regimes such as low-protein diet or Mediter-
ranean diet reduce renal function decline and
mortality rate in CKD [41, 42]. Hence, dietary
advice is recommended in accordance with
CKD severity to control for daily calorie, salt,
potassium, phosphate and protein intake
[3, 33]. However, patients with consistently
elevated serum phosphate levels or metabolic
acidosis [low serum bicarbonate levels
(\22 mmol/l)], associated with increased risk of
CKD progression and death, may be treated
with phosphate binding agents (e.g. aluminium
hydroxide and calcium carbonate) or sodium
bicarbonate, respectively [3].
To reduce the risk of cardiovascular disease,
KDIGO and NICE recommend active lipid
management and blood pressure control
[33, 43, 44]. In early CKD stages 1 and 2, statins
are recommended for all patients over 50 years
of age, whilst in stage 3 and advanced stages of
the disease, stage 4–5 (eGFR\60 mL/min per
1.73 m2), a combination of statins and ezetim-
ibe is advised [43].
Management of hypertension includes a
target blood pressure of less than 140/90 mmHg
for patients with CKD and hypertension and
less than 130/80 mmHg for patients with CKD
and T2DM, and also in patients with albumin-
uria [3, 32], alongside blood pressure lowering
therapies and renin–angiotensin–aldosterone
system (RAAS) blocking agents, such as angio-
tensin receptor blockers (ARB) or angiotensin-
converting enzyme inhibitors (ACEi). As such,
RAAS inhibitors (RAASi) are currently recom-
mended to treat patients with diabetes, hyper-
tension and albuminuria in CKD [45]. These
RAAS blocking agents confer both renal and
cardiovascular protection and are recom-
mended as first-line treatment to treat hyper-
tension in patients with CKD [34, 46].
The clinical benefits of RAASi have been
demonstrated in patients with CKD with and
without diabetes [47–49]. These clinical benefits
are in addition to their effects on reducing
blood pressure and albuminuria, including a
reduction in eGFR decline and a decreased risk
of ESKD cardiac-related morbidity and all-cause
mortality [47–49]. Nevertheless, despite their
benefits, RAASi treatment can induce
hyperkalaemia, and patients are often advised
to reduce RAASi dosage or even discontinue
their treatment, which prevents optimum clin-
ical benefits of RAASi therapy being reached. In
this instance, combination therapy with potas-
sium binding agents, such as patiromer and
sodium zirconium cyclosilicate, may be used
alongside RAASi therapy to reduce RAASi-asso-
ciated hyperkalaemia.
However long-term trials will be required to
determine their effect on cardiovascular mor-
bidity and mortality in CKD [50–52]. Despite
these therapies being the mainstay of CKD
management, there is still a residual risk of CKD




Over the last 2 years, novel therapeutic
approaches for CKD management have
emerged, with particular attention on miner-
alocorticoid receptor antagonists (MRAs) and
sodium–glucose co-transporter 2 (SGLT2) inhi-
bitors. The clinical effectiveness of finerenone, a
selective oral, non-steroidal MRA, has recently
been demonstrated to lower risks of CKD pro-
gression and cardiovascular events in diabetic
kidney disease (DKD) [53]. Finerenone is under
review for approval by the European Medicines
Agency (EMA) and US Food and Drug Admin-
istration (FDA).
Of these new and emerging therapies,
SGTL2i offers the most clinical benefit with
both cardiovascular and renal protective effects,
independent of glucose lowering. Clinical trials
of SGTL2 in T2DM with and without CKD
overall showed a 14–31% reduction in cardio-
vascular endpoints including hospitalisation for
HF and MACE and a 34–37% reduction in hard
renal-specific clinical endpoints including a
sustained reduction in eGFR, progression of
albuminuria and progression to ESKD [54–58].
CREDENCE, was a double-blind, multicentre,
randomised trial in diabetic patients with
albuminuric CKD (eGFR 30 to\90 mL/min per
1.73 m2 and ACR C 30 mg/mmol) [57]. In this
trial, canagliflozin reduced the relative risk of
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the composite of ESKD, doubling of serum cre-
atinine and renal-related mortality by 34%,
relative risk of ESKD by 34% and risk of car-
diovascular-related morbidity, including
myocardial infarction and stroke, and
mortality.
The SGTL2i dapagliflozin has proven its
effectiveness in slowing CKD progression in
addition to reducing cardiovascular risk in early
stages of CKD. The DECLARE-TIMI58 trial
involved 17,160 diabetic patients with estab-
lished atherosclerotic cardiovascular disease
and early-stage CKD (mean eGFR was 85.2 mL/
min per 1.73 m2) and were randomised to
receive either dapagliflozin or placebo. Follow-
ing a median follow-up of 4.2 years, there was a
significant reduction in renal composite end-
points with dapagliflozin versus placebo, with a
46% reduction in sustained decline of at least
40% eGFR to less than 60 mL/min per 1.73 m2
and a reduction in ESKD (defined as dialysis for
at least 90 days, kidney transplantation, or
confirmed sustained eGFR\ 15 mL/min per
1.73 m2) or renal death.
More recently, these cardiovascular and
renal protective effects of SGTLT2i have also
been demonstrated in a broad range of patients
with more advanced stages of CKD (mean eGFR
was 43.1 ± 12.4 mL/min per 1.73 m2) without
diabetes [58, 59]. In the DAPA-CKD trial, many
patients were without diabetes, including IgA
nephropathy, ischemic/hypertension
nephropathy and other glomerulonephritis
[59]. Patients receiving dapagliflozin had a 39%
relative risk reduction in the primary composite
outcomes of a sustained decline in eGFR of at
least 50%, ESKD and renal- or cardiovascular-
related mortality and a 31% relative risk reduc-
tion of all-cause mortality compared to placebo
[58, 60]. Safety outcomes from clinical trials of
dapagliflozin have also shown similar inci-
dences of adverse events in both placebo and
dapagliflozin arms [58, 61].
The clinical benefits and safety outcomes
from these trials highlight the potential use of
SGTL2i in reducing cardiovascular burden and
CKD progression in a broad range of CKD aeti-
ologies at early and late stages where there is an
unmet need. Currently, SGTL2i class drugs,
including canagliflozin, dapagliflozin and
empagliflozin, are approved by the US FDA for
the treatment of T2DM and, more recently,
dapagliflozin and canagliflozin for CKD and
DKD respectively [62, 63]. In addition, SGTL2i
has been recommended for approval in the
European Union (EU) by the Committee for
Medicinal Products for Human Use (CHMP) of
the EMA, for the treatment of CKD in adults
with and without T2D [64]. Hence, there is now
a need to raise awareness of the clinical appli-
cability of these drugs in CKD to ensure full
utilisation and maximum benefits are met, for
both patients and providers.
CONCLUSION
This narrative review has summarised some of
the key challenges associated with CKD. Early
stages of the disease are clinically silent which
prevents early intervention to slow the pro-
gression of the disease and allows progression of
CKD and ESKD. At advanced stages of the dis-
ease, when clinical symptoms are present,
patients with CKD are already at heightened
risk of cardiovascular-related morbidity and
mortality. Hence, advanced stages of CKD and
ESKD are associated with poor outcomes and a
significant clinical and economic burden.
At present, there are no treatments to cure
CKD; as such, strategies for CKD management
have been developed to target the modifiable
risk factors in order to reduce cardiovascular
disease morbidity in patients with CKD and
slow the progression of CKD to ESKD. However,
despite available treatment options, residual
risk of adverse events and CKD progression
remain; hence, an unmet need exists in CKD
treatment. SGTL2i have the potential to fill this
gap, with recent evidence from clinical trials
showing a reduction in cardiovascular and renal
adverse endpoints in a broad range of patients
with CKD.
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